Moderna Phase III COVID-19 Vaccine Plan To Enroll 30,000 Patients

The company finalized the Phase III program based on feedback from the US FDA and plans to start the study in July. With a 100 µg dose, Moderna says it can manufacture 500 million doses a year.

Motion blurred racetrack,sunset scene
Moderna is moving a COVID-19 vaccine quickly into Phase III • Source: Shutterstock

Moderna Inc.'s Phase III development plan for its COVID-19 vaccine mRNA-1273 calls for enrolling roughly 30,000 patients in the US who will be treated with the 100 µg dose – the midrange dose studied in the Phase I trial. The biotech announced on 11 June that it finalized the Phase III study protocol based on feedback from the US Food and Drug Administration.

The company said it is advancing the 100µg dose because it is the optimal dose level to maximize the immune...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip